Resume of Supervisor of Fujian Medical University
福建医科大学来华留学研究生指导教师简历

陈明水 Mingshui Chen

Institute（学院）：	Basic Medical Sciences	Deparment（科室）：	Immuno-Oncology Laboratory
Professional Title（专业职称）：	Senior Technologist	Teaching Title（教学职称）：	Lecturer
Contact（联系方式）：	/	E-mail（电子邮箱）：	838195033@qq.com

Work Experience（工作经历）

Period（起止时间）	Institution/University, City, Country（国家/大学/机构/职称）
08,1991-Present	Senior Technologist, Fujian Cancer Hospital＆Institute, Fuzhou，China

Education（教育背景）

When&where to obtain the highest degree（何时何校获最高学位及学历）

Period（起止时间）	University, City, Country（国家/大学/最高学位）
09,1987-07,1991	Bachelor, Fujian Medical University
09,2006-11.2009	Master, Fujian Medical University

Overseas Experience出国经历

including study, research and foreign aid（含留学、援外、研修）

Period（起止时间）	Institution/University, City, Country（国家/大学/机构/职称）
2007-2008	Visiting Scholar, Moores UCSD Cancer Center, University of California-San Diego, USA
2016-2017	Visiting Scholar, Australian Institute for Bioengineering and Nanotechnology,The University of Queensland,Australia

Major & Research Direction（招生专业及研究方向）

Displine Level I（一级学科）	Displine Level II&III（专业名称：二科+三级学科）	Research Direction（研究方向及专长）	Level（层次）	Type（学位类型）
Basic Medicine	Immunology（Tumor immunology）	Basic reseach and clinic application for tumor immunity	☐P.H.D/M.D ☑Master	☑Academic ☐Professional
			☐P.H.D/M.D ☐Master	☐Academic ☐Professional

Personal Profile（基本情况简介）

(around 150 words, including basic introduction, research direction, teaching experience as supervisor for international students)

Areas of Expertise

1) Cancer vaccines & immunotherapy 2) T-cell epitopes and activation 3) Immunoregulation of tumor immunity 4) Nanotechnology-based cancer immunotherapy.

Research efforts were focused on the development of T Lymphocyte Recognition of Antigens and Applications to Vaccines for Cancer.Identification of new target antigens for T cell activation, regulation, and effector function, develop more effective immunotherapy strategies for cancer. Currently working on the development of nanotechnology-based tools and platform technologies for cancer immunotherapy applications. Utilizing several tumor antigen-derived peptides encapsulated in PLGA nanoparticles in an attempt to induce potent and specific CTL responses against the tumor-specific antigens baring tumor. Using nanoparticles payloaded with chemotherapeutics/siRNA and coated with antibodies/ligands that direct the nanoparticles to the tumor for targeted therapy. Investigating blocked negative signal pathway by SHP2, A2AR inhibitors to enhance T cell anti-tumor response.